Comparison of association of the risk of major adverse cardiovascular events between BNT162b2 and CoronaVac among individuals with cardiovascular disease
Latest Information Update: 11 Aug 2022
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 11 Aug 2022 New trial record
- 27 Jul 2022 Results published in the Cardiovascular Research